文献速递妇科肿瘤

晚期卵巢癌维持治疗试验中的信息性删失对治疗获益的影响

Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit.
PubMed 文献 · Eur J Cancer · 2026-01-11

该研究评估了晚期卵巢癌维持治疗试验中信息性删失对无进展生存期(PFS)的影响。

要点

  • 信息性删失可显著高估卵巢癌维持治疗试验的PFS获益。
  • 敏感性分析显示HR随删失比例增加而逐渐减小。
  • PARP抑制剂试验中治疗持续时间短于PFS中位数。

核心结论

  • 信息性删失可显著扭曲卵巢癌维持治疗试验中的PFS获益估计。
  • 透明报告删失率及其原因对临床解读至关重要,应成为所有随机维持治疗试验的标准。

研究设计与样本

  • 选取双盲、安慰剂对照的维持治疗试验,从已发表的生存曲线重建个体患者数据。
  • 进行敏感性分析,将不同比例的删失事件重新分类为进展,模拟0%至100%信息性删失的情景。
  • 重新估计风险比(HR)并与原始报告值比较,同时比较治疗持续时间与PFS。

主要发现

  • HR逐渐减小,10%删失时减少6%,100%删失时减少29%。
  • 在9项PARP抑制剂试验中,治疗持续时间短于PFS(中位数均值12.5 vs 17.6个月)。
  • 限于PARP抑制剂研究时结果一致。
  • 未观察到不良事件与删失之间的相关性。

临床怎么用

  • 解读卵巢癌维持治疗试验的PFS结果时需考虑信息性删失的影响。
  • 应要求试验透明报告删失率及原因以支持临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A considerable proportion of patients in ovarian cancer maintenance trials may be censored in progression-free survival (PFS) analyses, the primary study endpoint. Such censoring is often informative, reflecting discontinuation due to toxicity, preference, or early switch to alternative therapies, potentially biasing results toward overestimating PFS benefit. We aimed to quantify the impact of informative censoring on PFS in these trials. METHODS: Double-blind, placebo-controlled maintenance therapy trials were selected, and individual patient data reconstructed from published survival curves. A sensitivity analysis reclassified varying proportions of all censored events as progressions to model scenarios from 0 % to 100 % informative censoring. Hazard ratios (HRs) were re-estimated and compared with the originally reported values. Duration of therapy was compared with PFS. RESULTS: Twenty-two trial units (N = 8256) were included. Nineteen reported statistically significant results, falling to 14 (74 %) at the upper limit of analysis. HRs diminished progressively, with a 6 % reduction at 10 % censoring and 29 % at 100 %. In nine PARP inhibitor trials, treatment duration was shorter than PFS (mean of medians = 12.5 vs 17.6 months). Results were consistent when limited to PARP inhibitor studies. No correlation was observed between adverse events and censoring. CONCLUSIONS: Informative censoring can substantially distort PFS benefit estimates in ovarian cancer maintenance trials. Transparent reporting of censoring rates and their causes is essential for meaningful clinical interpretation and should be standard in all randomised maintenance therapy trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Woodford R, Lord S, Decaria A, et al. Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit. Eur J Cancer. 2026. PMID: 41539181. doi:10.1016/j.ejca.2026.116231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。